Multiple myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...

This looked at patients with transplant-eligible newly diagnosed multiple myeloma ... survival [PFS], as well as overall ...

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

In a real-world study involving patients with standard-risk, newly-diagnosed multiple myeloma (NDMM), there was no significant ... Study findings were reported in the journal Bone Marrow ...

Johnson & Johnson seeks US & EU approvals for Darzalex Faspro/Darzalex as subcutaneous monotherapy for high-risk smoldering multiple myeloma: Raritan, New Jersey Monday, November ...

Multiple Myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...

Multiple Myeloma is a type of blood cancer that develops in plasma ... can provide patients with extended survival and ...

Detailed price information for Legend Biotech Corp ADR (LEGN-Q) from The Globe and Mail including charting and trades.

P-BCMA-ALLO1 elicited high response rates and a manageable safety profile in heavily pretreated, relapsed/refractory multiple myeloma. Follow-up from the CARTITUDE-4 trial showed that cilta-cel ...

Detailed price information for Adaptive Biotechnologies Corp (ADPT-Q) from The Globe and Mail including charting and trades.

and liver cancer. The 1-year relative survival rate for all cancers combined fell from 82.3% in the second quarter of 2018 to 77.5% in the second quarter of 2020. The COVID-19 pandemic reduced ...